Article

Safety and Tolerability of Solifenacin Add-on Therapy to α-Blocker Treated Men With Residual Urgency and Frequency

Weill Medical College of Cornell University, New York, New York 10065-4805, USA.
The Journal of urology (Impact Factor: 3.75). 12/2009; 182(6):2825-30. DOI: 10.1016/j.juro.2009.08.023
Source: PubMed

ABSTRACT VICTOR was a 12-week, double-blind, placebo controlled trial assessing the safety and tolerability of solifenacin plus tamsulosin in men with residual overactive bladder symptoms after tamsulosin monotherapy. Efficacy of solifenacin plus tamsulosin vs placebo plus tamsulosin was also evaluated.
A total of 398 men 45 years old or older were randomized to 12 weeks of solifenacin plus tamsulosin or placebo plus tamsulosin once daily. The study population had 8 or more micturitions per 24 hours and 1 or more urgency episode per 24 hours after taking tamsulosin for 4 or more weeks, a total International Prostate Symptom Score of 13 or greater, a Patient Perception of Bladder Condition score of 3 or greater, a post-void residual of 200 ml or less and a peak flow rate of 5 ml per second or greater. Adverse events were monitored throughout the study. The primary efficacy end point was mean change from baseline to week 12 in micturitions per 24 hours. Secondary measures included mean change in urgency episodes per 24 hours, and changes in Patient Perception of Bladder Condition, Urgency Perception Scale and total International Prostate Symptom Scores.
The most frequent adverse events in the solifenacin plus tamsulosin and placebo plus tamsulosin groups were dry mouth (7% and 3%, respectively) and dizziness (3% and 2%, respectively). Of the patients on solifenacin plus tamsulosin 7 (3%) reported retention and 3 required catheterization. No patients on placebo plus tamsulosin reported retention. Patients on solifenacin plus tamsulosin vs placebo plus tamsulosin showed larger reductions in frequency but not of statistical significance (-1.05 vs -0.67, p = 0.135). However, patients on solifenacin plus tamsulosin vs placebo plus tamsulosin did show statistically significant reductions in urgency (-2.18 vs -1.10, p <0.001). Patient reported outcome measures showed no significant between group differences.
Solifenacin plus tamsulosin was well tolerated. There was a low incidence of urinary retention requiring catheterization. At week 12 solifenacin plus tamsulosin decreased daily micturitions and urgency episodes. Only urgency reached statistical significance vs placebo plus tamsulosin.

1 Follower
 · 
187 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Overactive bladder (OAB) is characterized by involuntary detrusor contractions that result in bothersome urinary symptoms. The estimated US prevalence of OAB is 16% among men and 16.9% among women, comprising some 37.4 million Americans. The mainstay of treatment is medication. Although all drugs have variable degrees of efficacy and tolerability, several have emerged that yield good clinical results with tolerable side effects. This review focuses on two frequently prescribed drugs, solifenacin and tolterodine, and compares their clinical efficacy. A PubMed review was conducted with “solifenacin” and “tolterodine” as search words. Articles that compared the two medications were reviewed for content and number of study participants. Those with the most relevant findings and the highest number of participants were included. Both solifenacin and tolterodine show clinical efficacy for the treatment of OAB. Solifenacin seems to have better results in some series, with similar side effects. Antimuscarinic therapy is effective as OAB treatment. Both solifenacin and tolterodine have good clinical efficacy. However, in head—to-head trials, solifenacin seems to have somewhat better outcomes. Solifenacin, 5mg, has less reported dry mouth than tolterodine, but at 10mg, the incidence of dry mouth is similar. KeywordsOveractive bladder–Detrusor instability–Solifenacin–Tolterodine–Antimuscarinic antagonist–Antimuscarinic receptor–Urinary urgency–Urinary frequency
    Current Bladder Dysfunction Reports 03/2010; 6(1):1-6. DOI:10.1007/s11884-010-0075-2
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives: TAABO was a randomized, controlled trial to evaluate the efficacy and safety of combination therapy of tamsulosin (TAM) with propiverine (PROP) in men with both benign prostatic hyperplasia and overactive bladder.Methods: It enrolled men 50 years or older who had an international prostate symptom score (IPSS) of 8 or higher, an urgency item score of 1 or higher, and a quality of life (QOL) score of 2 or higher. After 8 weeks of TAM 0.2 mg/day, patients who met the inclusion criteria (8 micturitions per 24 h and 1 urgency per 24 h, evaluated by bladder diary) and were eligible for 12-weeks of continued Treatment II. Five hundred and fifteen patients were enrolled. Thereafter, 214 patients were assigned randomly to receive either TAM alone (n = 67), TAM plus PROP 10 mg (n = 72), or TAM plus PROP 20 mg (n = 75) in Treatment II. The primary efficacy end point was a change in micturitions per 24 h documented in the bladder diary. The change from baseline in urgency episodes per 24 h, IPSS, IPSS/QOL subscore, urinary flow rate and postvoid residual volume were assessed as secondary efficacy measures.Results: A total of 141 men (47 TAM, 49 TAM plus PROP 10 mg, and 45 TAM plus PROP 20 mg patients) were assessed by week 12. Compared with the TAM, TAM plus PROP 10 mg patients experienced significantly fewer micturitions (P = 0.0261), urgencies (P = 0.0093) per 24 h, lower IPSS storage (P = 0.0465), and IPSS urgency (P = 0.0252) subscores.Conclusions: These results suggest that combining TAM and 10 mg of PROP for 12 weeks provides added benefit for men with both benign prostatic hyperplasia and overactive bladder.
    Lower urinary tract symptoms 09/2010; 3(1):29 - 35. DOI:10.1111/j.1757-5672.2010.00081.x · 0.54 Impact Factor
Show more

Preview

Download
9 Downloads
Available from